These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 24825342)

  • 1. Topical rather than intradermal application of the TLR7 ligand imiquimod leads to human dermal dendritic cell maturation and CD8+ T-cell cross-priming.
    Fehres CM; Bruijns SC; van Beelen AJ; Kalay H; Ambrosini M; Hooijberg E; Unger WW; de Gruijl TD; van Kooyk Y
    Eur J Immunol; 2014 Aug; 44(8):2415-24. PubMed ID: 24825342
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Topical imiquimod has therapeutic and immunomodulatory effects against intracranial tumors.
    Xiong Z; Ohlfest JR
    J Immunother; 2011 Apr; 34(3):264-9. PubMed ID: 21389872
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intradermal delivery of TLR agonists in a human explant skin model: preferential activation of migratory dendritic cells by polyribosinic-polyribocytidylic acid and peptidoglycans.
    Oosterhoff D; Heusinkveld M; Lougheed SM; Kosten I; Lindstedt M; Bruijns SC; van Es T; van Kooyk Y; van der Burg SH; de Gruijl TD
    J Immunol; 2013 Apr; 190(7):3338-45. PubMed ID: 23467931
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In situ Delivery of Tumor Antigen- and Adjuvant-Loaded Liposomes Boosts Antigen-Specific T-Cell Responses by Human Dermal Dendritic Cells.
    Boks MA; Bruijns SCM; Ambrosini M; Kalay H; van Bloois L; Storm G; Gruijl T; van Kooyk Y
    J Invest Dermatol; 2015 Nov; 135(11):2697-2704. PubMed ID: 26083554
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The TLR-7 agonist, imiquimod, enhances dendritic cell survival and promotes tumor antigen-specific T cell priming: relation to central nervous system antitumor immunity.
    Prins RM; Craft N; Bruhn KW; Khan-Farooqi H; Koya RC; Stripecke R; Miller JF; Liau LM
    J Immunol; 2006 Jan; 176(1):157-64. PubMed ID: 16365406
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Priming CD8+ T cells with dendritic cells matured using TLR4 and TLR7/8 ligands together enhances generation of CD8+ T cells retaining CD28.
    Pufnock JS; Cigal M; Rolczynski LS; Andersen-Nissen E; Wolfl M; McElrath MJ; Greenberg PD
    Blood; 2011 Jun; 117(24):6542-51. PubMed ID: 21493800
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The impact of imiquimod, a Toll-like receptor-7 ligand (TLR7L), on the immunogenicity of melanoma peptide vaccination with adjuvant Flt3 ligand.
    Shackleton M; Davis ID; Hopkins W; Jackson H; Dimopoulos N; Tai T; Chen Q; Parente P; Jefford M; Masterman KA; Caron D; Chen W; Maraskovsky E; Cebon J
    Cancer Immun; 2004 Sep; 4():9. PubMed ID: 15384929
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Influenza A infection enhances cross-priming of CD8+ T cells to cell-associated antigens in a TLR7- and type I IFN-dependent fashion.
    Wei J; Waithman J; Lata R; Mifsud NA; Cebon J; Kay T; Smyth MJ; Sadler AJ; Chen W
    J Immunol; 2010 Nov; 185(10):6013-22. PubMed ID: 20956347
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TLR7 triggering with polyuridylic acid promotes cross-presentation in CD8α+ conventional dendritic cells by enhancing antigen preservation and MHC class I antigen permanence on the dendritic cell surface.
    Crespo MI; Zacca ER; Núñez NG; Ranocchia RP; Maccioni M; Maletto BA; Pistoresi-Palencia MC; Morón G
    J Immunol; 2013 Feb; 190(3):948-60. PubMed ID: 23284054
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nano-particle vaccination combined with TLR-7 and -9 ligands triggers memory and effector CD8⁺ T-cell responses in melanoma patients.
    Goldinger SM; Dummer R; Baumgaertner P; Mihic-Probst D; Schwarz K; Hammann-Haenni A; Willers J; Geldhof C; Prior JO; Kündig TM; Michielin O; Bachmann MF; Speiser DE
    Eur J Immunol; 2012 Nov; 42(11):3049-61. PubMed ID: 22806397
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Monocyte-derived dendritic cells loaded with a mixture of apoptotic/necrotic melanoma cells efficiently cross-present gp100 and MART-1 antigens to specific CD8(+) T lymphocytes.
    von Euw EM; Barrio MM; Furman D; Bianchini M; Levy EM; Yee C; Li Y; Wainstok R; Mordoh J
    J Transl Med; 2007 Apr; 5():19. PubMed ID: 17448240
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cross-priming CD8+ T cells by targeting antigens to human dendritic cells through DCIR.
    Klechevsky E; Flamar AL; Cao Y; Blanck JP; Liu M; O'Bar A; Agouna-Deciat O; Klucar P; Thompson-Snipes L; Zurawski S; Reiter Y; Palucka AK; Zurawski G; Banchereau J
    Blood; 2010 Sep; 116(10):1685-97. PubMed ID: 20530286
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunogenicity in humans of a transdermal multipeptide melanoma vaccine administered with or without a TLR7 agonist.
    Meneveau MO; Petroni GR; Salerno EP; Lynch KT; Smolkin M; Woodson E; Chianese-Bullock KA; Olson WC; Deacon D; Patterson JW; Grosh WW; Slingluff CL
    J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 34035112
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The use of Toll-like receptor 7/8 agonists as vaccine adjuvants.
    Vasilakos JP; Tomai MA
    Expert Rev Vaccines; 2013 Jul; 12(7):809-19. PubMed ID: 23885825
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transcutaneous immunization with a novel imiquimod nanoemulsion induces superior T cell responses and virus protection.
    Lopez PA; Denny M; Hartmann AK; Alflen A; Probst HC; von Stebut E; Tenzer S; Schild H; Stassen M; Langguth P; Radsak MP
    J Dermatol Sci; 2017 Sep; 87(3):252-259. PubMed ID: 28655469
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Single-step antigen loading and activation of dendritic cells by mRNA electroporation for the purpose of therapeutic vaccination in melanoma patients.
    Bonehill A; Van Nuffel AM; Corthals J; Tuyaerts S; Heirman C; François V; Colau D; van der Bruggen P; Neyns B; Thielemans K
    Clin Cancer Res; 2009 May; 15(10):3366-75. PubMed ID: 19417017
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 9-Phenanthrol enhances the generation of an CD8
    Hartmann AK; Aranda Lopez P; Zajac M; Freichel M; Schild H; Radsak MP; Stassen M
    J Dermatol Sci; 2017 Sep; 87(3):260-267. PubMed ID: 28823644
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dendritic cells loaded with killed allogeneic melanoma cells can induce objective clinical responses and MART-1 specific CD8+ T-cell immunity.
    Palucka AK; Ueno H; Connolly J; Kerneis-Norvell F; Blanck JP; Johnston DA; Fay J; Banchereau J
    J Immunother; 2006; 29(5):545-57. PubMed ID: 16971810
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enhanced type I interferon signaling and recruitment of chemokine receptor CXCR3-expressing lymphocytes into the skin following treatment with the TLR7-agonist imiquimod.
    Wenzel J; Uerlich M; Haller O; Bieber T; Tueting T
    J Cutan Pathol; 2005 Apr; 32(4):257-62. PubMed ID: 15769273
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dual activation of Toll-like receptors 7 and 9 impairs the efficacy of antitumor vaccines in murine models of metastatic breast cancer.
    Moreno Ayala MA; Gottardo MF; Gori MS; Nicola Candia AJ; Caruso C; De Laurentiis A; Imsen M; Klein S; Bal de Kier Joffé E; Salamone G; Castro MG; Seilicovich A; Candolfi M
    J Cancer Res Clin Oncol; 2017 Sep; 143(9):1713-1732. PubMed ID: 28432455
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.